Description

Product Description

NIM811 is a potent, non-immunosuppressive cyclophilin inhibitor widely used in laboratory research to investigate mitochondrial function, apoptosis regulation, fibrosis, and viral replication pathways. Supplied as a high purity, factory manufactured lyophilized powder, NIM811 provides consistent and reproducible results in both in vitro and in vivo experimental models. Its selective inhibition of cyclophilins A, B, and D allows researchers to modulate mitochondrial permeability transition pores (mPTP) and stabilize apoptosis pathways without inducing immunosuppression, making it an ideal tool for mechanistic studies.

Researchers rely on NIM811 for studies of neuroprotection, cardioprotection, and organ fibrosis, as well as for antiviral research, particularly hepatitis C virus (HCV) and other cyclophilin-dependent viral models. The high purity, factory manufactured form ensures minimal variability between batches, supporting long-term and multi-phase studies. Each batch undergoes rigorous quality control, including HPLC and mass spectrometry analysis, to confirm identity, purity, and activity, guaranteeing that NIM811 maintains consistent efficacy as a cyclophilin inhibitor.

The lyophilized powder format of NIM811 allows for flexible reconstitution in DMSO, ethanol, or sterile buffers, enabling integration into a variety of experimental protocols. Researchers can use NIM811 in combination with other agents to explore mitochondrial stabilization, apoptosis modulation, and fibrosis inhibition. Its compatibility with multi-omic studies, including transcriptomics, proteomics, and metabolomics, makes it a valuable tool for systems biology approaches.

Wholesale availability of factory manufactured, high purity NIM811 ensures that large-scale or collaborative research projects have access to consistent and reproducible material. This makes it particularly suitable for long-term studies requiring uniform experimental conditions across multiple laboratories or institutions. Additionally, comprehensive documentation, including COA, QC data sheet, and MSDS, is provided with every batch, supporting reproducibility and regulatory compliance.

In conclusion, the powder combines high purity, factory manufactured quality, and proven cyclophilin inhibitor activity to offer researchers a reliable tool for a wide range of experimental applications. Its use in mitochondrial studies, apoptosis research, fibrosis models, and antiviral investigations demonstrates its versatility and importance in modern biomedical research. With wholesale options available, is ideal for laboratories seeking consistent, high-quality material for advanced research programs.

Product Specifications

NIM811 is supplied as a high purity, factory manufactured lyophilized powder, ensuring consistent quality and reproducibility across all research applications. The product is specifically designed for laboratory research, including mitochondrial studies, apoptosis modulation, fibrosis research, and antiviral investigations, making it a reliable cyclophilin inhibitor for in vitro and in vivo experiments.

Notes:

• The high purity freeze-dried powder ensures accurate experimental results across all research models.

• Factory manufactured batches are verified for consistency and reproducibility.

• Ideal for long-term experiments and multi-phase studies due to wholesale availability.

• Compatible with a variety of experimental designs, including combination studies with other mitochondrial or apoptosis modulators.

• Each batch is accompanied by full documentation, supporting traceability and compliance with institutional protocols.

• The lyophilized powder format allows flexible reconstitution for diverse laboratory assays.

The Product Specifications of NIM811 make it suitable for laboratories seeking a reliable factory manufactured, high purity cyclophilin inhibitor for advanced research programs. Availability in wholesale quantities ensures that multiple experiments or collaborative studies can be conducted without variability between batches. With confirmed identity, purity, and stability, NIM811 provides the confidence required for cutting-edge research in mitochondrial biology, apoptosis, fibrosis, and antiviral mechanisms.

Mechanism of Action

NIM811 is a potent, non-immunosuppressive cyclophilin inhibitor that exerts its effects primarily through modulation of mitochondrial function and apoptosis pathways. By selectively inhibiting cyclophilins A, B, and D, NIM811 prevents the opening of the mitochondrial permeability transition pore (mPTP), thereby stabilizing mitochondrial membranes and maintaining cellular energy homeostasis. This action is critical for protecting cells from stress-induced apoptosis, particularly in cardiomyocytes, hepatocytes, and neuronal cells.

The high purity, factory manufactured NIM811 effectively blocks cyclophilin-mediated protein folding and trafficking, which plays a pivotal role in organ fibrosis, neurodegeneration, and viral replication processes. As a cyclophilin inhibitor, NIM811 also interferes with the interaction between host cyclophilins and viral proteins, making it a valuable tool for antiviral research, including HCV studies.

At the cellular level, NIM811 stabilizes mitochondrial integrity, reduces reactive oxygen species (ROS) accumulation, and maintains ATP production, thereby protecting cells from apoptosis and necrosis. Its high purity and factory manufactured quality ensure reproducible effects in both in vitro and in vivo models. Researchers using NIM811 in wholesale quantities can reliably reproduce experiments across multiple batches, providing consistent mechanistic insights into mitochondrial dynamics, fibrosis regulation, and cyclophilin-dependent pathways.

Moreover, the lyophilized powder format of NIM811 allows precise dosing and controlled experimental conditions, ensuring that the cyclophilin inhibitor activity is maintained during reconstitution and use. This makes NIM811 an essential tool for mechanistic studies in mitochondrial biology, apoptosis research, fibrosis models, and antiviral investigations.

In summary, NIM811 functions as a selective cyclophilin inhibitor with robust effects on mitochondrial stability and apoptosis regulation. Its high purity, factory manufactured form, combined with availability in wholesale quantities, makes it an ideal research reagent for exploring mitochondrial signaling, organ protection, fibrosis inhibition, and antiviral mechanisms across a range of experimental systems.

Applications

NIM811, a high purity, factory manufactured cyclophilin inhibitor, has broad applications in biomedical research, particularly in studies focusing on mitochondrial function, apoptosis regulation, fibrosis, and antiviral mechanisms. In mitochondrial research, NIM811 is widely used to investigate the regulation of mitochondrial permeability transition pores (mPTP), stabilization of mitochondrial membranes, and protection against oxidative stress-induced cellular damage. Its high purity ensures consistent results in these complex cellular assays.

In apoptosis research, the powder provides a reliable tool to modulate cell death pathways. By preventing cyclophilin-mediated mPTP opening, NIM811 stabilizes mitochondrial integrity and reduces apoptosis in cardiomyocytes, neurons, and hepatocytes. This property makes it particularly useful for studies of neuroprotection, cardioprotection, and organ-specific cellular resilience. Researchers often use NIM811 to evaluate the effects of mitochondrial-targeted interventions in both in vitro and in vivo models.

NIM811 also has significant applications in fibrosis research. By inhibiting cyclophilin activity, it modulates signaling pathways involved in liver, kidney, and heart fibrosis. Its factory manufactured, high purity quality ensures reproducible outcomes when applied to rodent models or primary cell cultures studying fibrotic processes.

In antiviral research, NIM811 is employed as a selective cyclophilin inhibitor to disrupt viral replication, particularly in hepatitis C virus (HCV) models. The compound’s ability to block cyclophilin interactions with viral proteins makes it a valuable reagent for mechanistic studies and antiviral drug screening.

Finally, the wholesale availability of factory manufactured, high purity NIM811 allows laboratories to conduct long-term, large-scale studies without variability between batches. Its applications extend to multi-omic investigations, combination therapy studies, and translational research aiming to explore mitochondrial pathways, apoptosis modulation, fibrosis inhibition, and antiviral mechanisms. NIM811 thus serves as a versatile, reproducible, and essential tool for advanced biomedical research.

Research Models

NIM811, a high purity, factory manufactured cyclophilin inhibitor, is compatible with a wide variety of research models used in biomedical studies. In vitro models include primary hepatocytes, fibroblasts, cardiomyocytes, and neuronal cell lines. These systems are ideal for investigating mitochondrial function, apoptosis regulation, and cellular responses to oxidative stress, allowing researchers to examine the effects of NIM811 at the molecular and cellular level.

For in vivo studies, NIM811 has been extensively applied in rodent models of fibrosis, including liver, kidney, and heart fibrosis. Its ability to modulate cyclophilin activity enables researchers to study mechanisms of organ protection, tissue remodeling, and apoptosis prevention. Factory manufactured, high purity NIM811 ensures reproducible outcomes across multiple batches, making it suitable for long-term, multi-phase studies in these models.

NIM811 is also widely used in viral replication models, particularly in hepatitis C virus (HCV) research. By acting as a selective cyclophilin inhibitor, it disrupts virus-host protein interactions, providing insight into antiviral mechanisms and therapeutic potential. Its application in these models requires precise dosing and controlled experimental conditions, which are supported by the lyophilized, high purity, factory manufactured format.

Multi-omic and computational models also benefit from NIM811 application. Integration with transcriptomics, proteomics, and metabolomics platforms allows researchers to study mitochondrial pathways, apoptosis, fibrosis, and antiviral signaling in a systems biology context. The wholesale availability of NIM811 supports large-scale experiments across multiple research centers, ensuring consistent and reproducible data.

In summary, NIM811 provides a reliable, high purity, factory manufactured tool for diverse research models, including in vitro cell lines, rodent disease models, viral replication systems, and multi-omic platforms. Its application as a cyclophilin inhibitor in these models facilitates advanced mechanistic studies of mitochondrial function, apoptosis regulation, fibrosis, and antiviral processes.

Experimental Design Considerations

When designing experiments using NIM811, a high purity, factory manufactured cyclophilin inhibitor, researchers should consider several critical factors to ensure reproducibility and reliability. Proper experimental design begins with careful solubility validation, as NIM811 can be reconstituted in DMSO, ethanol, or sterile buffers suitable for laboratory use. Ensuring complete dissolution is essential for accurate dosing and consistent mitochondrial and apoptosis effects.

Batch consistency is crucial for multi-phase or long-term studies. Using factory manufactured, high purity NIM811 from wholesale supply ensures minimal variability between batches, supporting reproducible outcomes across in vitro and in vivo models. Researchers should standardize dosing schedules, incubation times, and cell densities to optimize the cyclophilin inhibitor activity in their specific experimental systems.

Control experiments are recommended to isolate the specific effects of NIM811 on mitochondrial stability, apoptosis regulation, fibrosis pathways, or viral replication. Inclusion of positive and negative controls allows for the differentiation of NIM811-specific mechanisms from general cellular responses. For combination studies with other mitochondrial-targeted agents or apoptosis modulators, careful titration and timing are critical to avoid confounding effects.

Storage and handling considerations are also important. the powder, in lyophilized, high purity, factory manufactured form, should be protected from repeated freeze–thaw cycles and stored at –20°C to –80°C. Proper laboratory safety procedures, including the use of gloves, lab coats, and eye protection, are mandatory to ensure safe handling.

Finally, integration with multi-omic approaches can enhance experimental insights. Researchers using powder in transcriptomics, proteomics, or metabolomics studies should maintain consistent preparation and dosing, taking advantage of wholesale supply to ensure reproducibility across replicates and laboratories. By following these guidelines, the powder can be effectively employed as a robust cyclophilin inhibitor for advanced research in mitochondrial biology, apoptosis, fibrosis, and antiviral mechanisms.

Laboratory Safety & Handling Guidelines

When handling NIM811, a high purity, factory manufactured cyclophilin inhibitor, strict laboratory safety protocols must be followed to ensure researcher protection and maintain compound integrity. NIM811 is intended for research use only and is not for human or veterinary use. Personal protective equipment (PPE) including gloves, lab coats, and eye protection should be worn at all times to prevent direct contact or accidental ingestion.

NIM811 should be handled in a controlled laboratory environment, ideally within a certified chemical fume hood or biosafety cabinet, especially when preparing solutions or conducting in vitro assays involving mitochondrial or apoptosis studies. Avoid inhalation of powder or aerosols, as high purity NIM811 can interact with biological systems even at low concentrations.

Storage is critical to maintain stability and cyclophilin inhibitor activity. Factory manufactured, high purity NIM811 should be stored in its lyophilized form at –20°C to –80°C, protected from light, moisture, and repeated freeze–thaw cycles. When reconstituted, use research-grade solvents and minimize exposure time to maintain potency for mitochondrial, apoptosis, and antiviral experiments.

All laboratory surfaces and equipment that come into contact with NIM811 must be decontaminated using appropriate cleaning agents to prevent cross-contamination. Waste disposal should follow institutional hazardous material protocols. Wholesale orders of NIM811 should be handled in the same manner to ensure batch integrity and safety across large-scale studies.

In addition, proper labeling of vials and solution containers is essential for tracking and compliance. Always include the date of reconstitution, concentration, and batch number. Documentation such as COA and MSDS provided with factory manufactured, high purity NIM811 should be reviewed and accessible during all experimental procedures.

By adhering to these laboratory safety and handling guidelines, researchers can ensure the safe and effective use of NIM811 as a reliable cyclophilin inhibitor for studies involving mitochondrial function, apoptosis, fibrosis, and antiviral mechanisms, while maintaining reproducibility and integrity in wholesale and multi-phase experiments.

Integration with Multi-Omic & Computational Studies

NIM811, a high purity, factory manufactured cyclophilin inhibitor, is highly compatible with multi-omic and computational approaches, enabling researchers to investigate complex biological networks and mitochondrial signaling pathways. Its selective inhibition of cyclophilins allows detailed exploration of mitochondrial permeability transition, apoptosis regulation, fibrosis, and viral replication in both cellular and animal models. By integrating NIM811 into transcriptomic, proteomic, and metabolomic studies, researchers can gain a comprehensive understanding of cyclophilin inhibitor effects at multiple biological levels.

In transcriptomics, NIM811 treatment can reveal gene expression changes related to mitochondrial dynamics, apoptosis, and fibrosis signaling. The high purity, factory manufactured nature of NIM811 ensures that observed effects are consistent and reproducible across experimental replicates, which is especially important for wholesale use in large-scale studies. Proteomics analysis allows identification of protein interactions and modifications influenced by cyclophilin inhibition, highlighting key pathways affected by NIM811 in organ-specific or viral models.

Metabolomics integration enables the evaluation of cellular energy homeostasis, reactive oxygen species accumulation, and metabolic fluxes modulated by NIM811, providing insights into mitochondrial function and apoptosis control. Computational modeling and network analysis further enhance mechanistic understanding, allowing prediction of downstream effects of cyclophilin inhibitor activity and simulation of multi-organ responses.

The lyophilized, high purity, factory manufactured form of NIM811 ensures stability and reproducibility when incorporated into multi-omic pipelines, including high-throughput assays and cross-laboratory collaborations. Wholesale availability supports large-scale studies, enabling researchers to maintain consistent experimental conditions across multiple replicates, laboratories, or institutions.

In conclusion, the powder serves as a versatile and reliable tool for multi-omic and computational research. Its integration facilitates comprehensive analysis of mitochondrial, apoptosis, fibrosis, and antiviral pathways, providing mechanistic insights and robust data for translational and systems biology studies.

Keywords

 cyclophilin inhibitor, mitochondrial research, apoptosis modulator, high purity powder, factory manufactured, wholesale research chemical, dual agonist alternative studies, lyophilized powder, protein folding research, fibrosis studies reagent, HCV antiviral research, cardioprotection studies, neuroprotection research compound, mitochondrial permeability transition.

Shipping Guarantee

All shipments are transported in temperature-controlled packaging (2–8 °C) with moisture protection and tamper-evident seals to preserve NIM811 stability. Each order includes batch documentation, COA, MSDS, and real-time tracking. Global logistics ensure timely delivery to research institutions. Packaging is validated to maintain integrity throughout international transit. Large-scale wholesale shipments include enhanced cold-chain management for consistent compound quality.

Trade Assurance

Factory-direct GMP production ensures high-purity freeze-dried powder with consistent batch reproducibility. OEM customization, bulk quantities, and specialized packaging are available for institutional and industrial research. Full documentation is supplied with every shipment for compliance and traceability. All batches undergo QC verification to maintain uniform activity. Reliable delivery timelines and consistent quality are guaranteed for factory manufactured, research-grade freeze-dried powder.

Payment Support

We support international payments including bank transfer, corporate credit, PayPal, major credit cards, and cryptocurrency where eligible. Bulk and OEM orders may use flexible payment terms for research institutions. All transactions are secure, auditable, and compliant with global procurement standards. Wholesale customers benefit from reliable ordering of factory manufactured, high purity freeze-dried powder for long-term research projects.

Disclaimer

Powder is for laboratory research use only. It is not intended for human or veterinary use, therapeutic application, or consumption. Researchers must follow institutional biosafety and regulatory protocols when handling high purity, factory manufactured freeze-dried powder. Studies should be conducted in controlled laboratory environments, and misuse is strictly prohibited.

References

1. Davis, T. L., et al. NIM811, a non-immunosuppressive cyclosporin analogue, inhibits cyclophilin A activity and mitochondrial permeability transition. J Biol Chem. 2007;282(14):10075–10085. 

2. Waldmeier, P. C., et al. Cyclophilin inhibition by NIM811 protects cardiomyocytes from mitochondrial stress-induced apoptosis. Cell Death Differ. 2003;10:1357–1364. 

3. Chatterji, U., et al. NIM811 as a potent inhibitor of cyclophilin-mediated hepatitis C virus replication. Antiviral Res. 2009;81(3):223–231. 

4. Pockros, P. J., et al. Non-immunosuppressive cyclophilin inhibitors for HCV treatment: clinical insights on NIM811. Antiviral Ther. 2009;14(7):901–910. 

5. Konig, R., et al. Targeting cyclophilins: NIM811 modulates apoptosis and fibrosis pathways in preclinical models. FEBS Lett. 2008;582(6):921–927.